Skip to main content

Table 3 Multivariate analysis of factors affecting RFS of patients with breast cancers of different molecular subtypes

From: KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Clinico-pathological feature Luminal A Luminal B TNBC with basal-like p value, (HR;CI) HER2-enriched
p value (HR;CI) p value (HR;CI) p value (HR; CI)
Age (≤ 35, 36–60,> 60 years) 0.014
Lymph node stage 0.025*
 Stage 2     0.031 (3.805; 1.130–12.811)
 Stage 3     0.005 (6.487;1.740–24.180)
Claudin-low 0.004
5.506 (1.710–17.734)
Overall KIBRA-low
  1. *Significant only for the lymph node stage 3;p, significance; HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor2; KIBRA-low; low expression of KIBRA in both cytoplasm and nucleus